Over the past two decades, studies from North America and Europe have found elevated HIV seroprevalence among people with severe mental illness (Ayuso-Mateos et al., 1997; Cournos & McKinnon, 1997; Rosenberg et al., 2001) . A history of injection drug use, multiple partners, trading sex for money or other goods, and low levels of condom use contribute to risk (Meade & Sikkema, 2005) . These findings show that in settings with low prevalence in the general population, many people with severe mental illness (SMI) are exposed to sexual risk situations. Recognition of this vulnerability spurred the development and testing of prevention interventions tailored for this population (Carey et al., 2004; Collins, Geller, Miller, Toro, & Susser, 2001; Otto-Salaj, Kelly, Stevenson, Hoffmann, & Kalichman, 2001; Susser et al., 1998) .
In the high-prevalence countries of southern Africa, where the pandemic taxes resources for HIV prevention, care, and treatment, the needs of people with mental illness can be easily overlooked if they are not identified as vulnerable to infection. The only published African seroprevalence study demonstrated that people with mental illness are indeed being infected. Sebit et al. found that 23.8% of consecutively admitted patients in a Zimbabwean psychiatric institution were HIV-positive (Acuda & Sebit, 1996) .
In South African psychiatric settings, unpublished pilot prevalence studies present a varied picture of HIV infection among people with SMI. At a psychiatric hospital in Gauteng Province 9% of 200 acute admissions were HIV-positive (Zingela, Esterhuizen, Kruger, & Webber, 2002) , a rate roughly comparable to provincial rates at that time. In KwaZulu Natal, the South African province with the highest HIV prevalence, a seroprevalence study among patients admitted with acute psychiatric symptoms to a psychiatric ward at an urban general hospital found a prevalence of 29.1% (Singh, Vasant, Nair, Karim, & Vardas, 2002) .
The current study accompanied our research team's HIV prevention training and intervention development in a group of public psychiatric institutions in KwaZulu Natal (Collins, Mestry, Wainberg, Nzama, & Lindegger, 2006) . While high HIV prevalence might have been expected in an urban general hospital setting, providers and administrators at the state psychiatric institutions were uncertain of the prevalence in the periurban and rural patient population. We systematically examined the HIV seropre-*Corresponding author. Email: pyc1@columbia.edu valence among psychiatric patients admitted to one such institution in KwaZulu Natal province.
Methods

Sample accrual
We aimed to recruit 150 participants, 75 female and 75 male, in order to have sufficient power to detect meaningful associations with HIV prevalence. Inclusion criteria were (1) age 18Á59 years and (2) ability to give informed consent. The study team screened the admission files of 278 patients (119 women and 159 men) admitted between 27 July and 14 November 2003 who met the age criterion for study inclusion. The ward file of each patient so screened was labeled to alert ward staff to contact the research team upon that patient's discharge. In addition, the research team contacted ward staff each day of the study to determine if there were any patients due for discharge that day. Patients were eligible for study participation only after consultation with the medical doctor who assessed them and determined that they were sufficiently stable for discharge. When patients who met the inclusion criteria were cleared for discharge, clinicians on the ward referred them to the research team.
This process yielded 179 patients over the course of the study: 93 women and 86 men. Research team members approached these patients for voluntary participation. Of this group, four patients were found ineligible upon closer review: two were subsequently confirmed to be over the age limit and two lacked capacity to consent to the study. From the remaining 175 eligible patients, we recruited 75 women and 76 men (n 0151). Sixteen patients refused to participate, and eight patients were discharged before they could be approached for consent. More women than men refused testing, and the most common reasons included lack of interest and a desire to consult with family or others before making a decision for testing.
The study received ethical approval by the University of KwaZulu Natal Ethics Committee, the Ethics Committee of the Midlands Psychiatric Complex, and the New York State Psychiatric Institute Institutional Review Board. The research team obtained informed consent using consent forms in English and isiZulu, the main language spoken by patients at the hospital. For participants who could not read, the consent form was read in isiZulu or English by the research team members. For those participants who could not write, a mark signifying their consent was placed on the consent form and witnessed. The participant received a copy of the signed form.
Specimen collection and analysis
The Orasure device was used to test oral mucosal transudate (OMT), an ultra filtrate of blood, for HIV antibodies. The Orasure device is an oral fluid test approved by the Food and Drug Administration (FDA) in the USA and has a sensitivity and specificity of 99.9% when used with the Vironostika HIV-1 Microelisa system (Gallo et al., 1997) . The test is particularly useful in resource-constrained settings as it remains stable at room temperature for 21 days and requires observation of a few simple quality control procedures. It has been used in the largest household survey of HIV prevalence in the country and has been recommended for use in South African surveillance studies (Shisana & Simbayi, 2002) .
A collection pad was positioned between the teeth and gums of the participant for 2Á5 minutes to obtain saliva samples. The pad was placed in a preservative solution and sent to a laboratory for testing using the Vironostika HIV-1 Microelisa system. All samples were stored at room temperature and sent by courier to the laboratory within nine days of collection. Specimens were transported in insulated containers with protective packaging. Technicians analyzed the samples at an accredited and experienced laboratory at the University of the Witwatersrand.
We conducted anonymous testing of the collected samples. The names of participants were removed from the data extraction sheet once the required data were collected. Study participants were informed that they could not be given their results since names were neither linked to bar code numbers nor to results. All participants were offered referral for diagnostic testing and pre-and post-test counseling by prior arrangement with the hospital. Each participant received a unique identifier bar code that was used for specimens, laboratory tracking, and reporting of results.
Measures
The research team obtained demographic characteristics (age, gender, race, marital status, region of residence, employment status), psychiatric and medical diagnosis and substance use data for the selected participants from the clinical chart.
Data analysis
The primary outcome was HIV status at the time of discharge from the psychiatric ward. This outcome was coded as a binary variable. Demographic variables were categorized for analysis as follows: age (18Á24, 25Á34 and 35 and above); race (Black versus Others); and marital status (currently married or single). Psychiatric diagnoses were broadly classified into schizophrenia spectrum disorders (including schizophrenia, schizophreniform disorder, schizoaffective disorder, and psychosis not otherwise specified), organic psychosis (substance-induced psychosis and psychosis due to a medical disorder), affective disorders (bipolar disorder and major depression), neurological conditions (epilepsy and developmental disorders), substance dependence, personality disorders and eating disorders. We created two separate variables from substance abuse data to indicate any use of cannabis and use of alcohol.
Missing data were treated as missing in the analyses. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). The data were analyzed using the statistical programs SPSS version 11.5 and SAS version 8.
Results
Demographics
The participants ranged in age from 18 to 59 years (Mean age 032). The majority of participants were Black (71.5%). Asian (14.6%), White (10.6%), and ''Colored'' 1 patients (3.3%) constituted the remainder of the sample. Most participants were unmarried (81%) and unemployed (82%). The majority of the sample was from KwaZulu Natal province (96.7%).
Clinical profile
HIV diagnoses
Eighteen participants (11.9%) had previously been diagnosed as HIV-positive and six (4%) were known to be HIV negative based on hospital records. Both groups are included in the sample.
Psychiatric diagnoses
Approximately, half of the patients (n 072, 47.7%) had a schizophrenia spectrum disorder and a quarter (n 039, 25.8%) had organic psychosis. About onefifth (n 029, 19.2%) were diagnosed with affective disorders. Other diagnoses included personality disorder (n 04, 2.7%), substance dependence (n01, 0.7%) and neurological conditions (n06, 4%). Seventy participants (46.3%) used some form of substance, which included cannabis (n 055, 36.4%), alcohol (n035, 23.2%), and other illicit drugs (n03, 2%).
HIV prevalence
Of the 151 participants, 40 tested positive for HIV (26.5%; 95% CI 019.37Á33.6). Differences in prevalence of infection between women (33.3%) and men (19.7%), which approached statistical significance, suggested that women were twice as likely to be infected with HIV as men (OR 2.03; p00.061; 95% CI 00.97Á4.27). Most HIV-positive participants (50%) were in the 25Á34 age group, followed by the 18Á24 year old group (25%), and the 35-plus age group (25%). Women in the 18Á24 and the 25Á34 age groups were more likely to be infected than their male counterparts. When we controlled for age, women were more likely to be infected than men (OR 2.74; 95% CI 01.25Á6.04; P 00.012). Among the various racial groups black participants were more likely to be infected than others (OR 6.29 95%CI, 1.97Á20.08; p00.002).
There were no significant differences in the prevalence of HIV among the psychiatric diagnostic groups (schizophrenia spectrum, 29.2%; organic psychosis, 28.2%; neurological conditions, 16.7%; affective disorder, 20.7%; personality and eating disorders, 25%). There were no significant associations between HIV status and marital status, employment status or substance use.
Discussion
We found an HIV prevalence of 26.5% among patients admitted to a state psychiatric hospital for acute psychiatric illness between July and November 2003. Women were almost twice as likely as men to be HIV-positive. Our results are comparable to the 29% prevalence rate found among acutely ill psychiatric patients at a general hospital in KwaZulu-Natal (Singh et al., 2002) . Data from the National HIV and Syphilis Antenatal Survey in 2003 showed a seroprevalence of 37.5% among women attending antenatal clinics in KwaZulu Natal, and the estimated prevalence for the general population was 20.9% for men and 24.5% for women (Department of Health, 2004) . In summary, the seroprevalence among this sample of people with SMI was higher than the general population estimate for the country, but lower than the rate among women attending antenatal clinics in KwaZulu Natal. Yet, the seroprevalence among women with SMI approached that of women attending antenatal clinics. Our findings reflect age and gender-related trends observed in the general population: participants in the 24Á34 year-old group were at higher risk, and women were at a higher risk than men (Department of Health, 2004) .
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Most seroprevalence studies of people with SMI have been conducted in high-income countries with low seroprevalence. The disproportionately high seroprevalence among men and women with SMI in those settings is believed to reflect the high prevalence of co-morbidities such as injection drug use and other illegal substance use in addition to high-risk sexual behaviors. In a hyperendemic country like South Africa with little injection drug use, the high prevalence of HIV in the general population makes it likely that the virus can be acquired shortly after sexual initiation; in that context, even if people with SMI may engage in high-risk sexual behaviors more than the general population, the result is that HIV prevalence largely matches the general population. In the USA, particularly in urban areas, the seroprevalence among people with SMI reflects the prevalence of the virus in poor and socially marginalized segments of the population. In South Africa, the rates among the general population are as high as those among people with SMI.
Our study suggests that people with SMI living in the midst of South Africa's high seroprevalence generalized epidemic are at great risk of becoming infected with HIV. Special efforts are needed to address this vulnerable and hard-to-reach population, and health care providers at psychiatric institutions are well placed to address the HIV prevention needs of people with mental illness. Despite systems and cultural barriers to implementing HIV prevention programs, HIV training programs tailored for the South African psychiatric setting have shown promise in increasing clinicians' knowledge of HIV and changing attitudes toward caring for people with HIV (Collins, 2006; Collins et al., 2006) . The hospitalization provides a window of opportunity after patients have been psychiatrically stabilized to promote HIV testing and conduct intensive risk reduction programs on short-stay wards while more comprehensive programs can benefit patients on longer admissions. The hospital where our study was conducted now has a risk reduction resource manual for which selected providers have received training.
Conclusion
Our findings demonstrate that in the midst of a generalized AIDS epidemic, people with mental illness must be included in both prevention and treatment efforts. They underscore the importance of integrated mental health and HIV care in institutional settings and affirm the need for detailed HIV risk assessment as a routine part of psychiatric care, integration of HIV prevention activities into both inpatient and outpatient services, and access to HIV care and treatment for people with psychiatric symptoms.
